Starting from the very first investigations on the vault nanoparticle, it was proposed that MVP/LRP upregulation (whose mechanisms are discussed in the previous paragraph (Section 3.4)) correlates with poor prognosis and resistance to chemotherapy in cancer—e.g., ovarian carcinoma [144], acute myeloid leukemia (AML) [160], and oral squamous cell carcinoma [164]. This evidence concerns the gene MVP and ovarian carcinoma.